---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089325"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:06.230450+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports Q3 FY2024 adjusted net loss $19.2M; EU/UK approval for LYTENAVA

## Summary
- GAAP net income $44.4M ($1.91 basic EPS), but diluted loss $0.89; adjusted net loss $19.2M ($0.83).
- Cash and equivalents $32.0M at June 30, 2024; raised $65M from private placements in March/April.
- EU and UK granted marketing authorization for LYTENAVA (bevacizumab gamma) for wet AMD.
- NORSE EIGHT trial enrollment at 359 of ~400 subjects; topline results expected Q4 CY2024.
- BLA resubmission for ONS-5010 on track for Q1 CY2025; US launch anticipated H2 CY2025.

## SEC filing metadata
- accession: 0001104659-24-089325
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465924089325/0001104659-24-089325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465924089325/tm2421547d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089325
- JSON: https://secwatch.observer/filing/0001104659-24-089325.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089325.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.